Prime Medicine Inc. (PRME) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Prime Medicine Inc. (PRME:NASDAQ), powered by AI.

Current Price
$2.87
P/E Ratio
-2.1
Market Cap
427M
Sector
Healthcare
What is the Prime Medicine Inc. stock price forecast?

Prime Medicine Inc. is currently trading at $2.87. View real-time AI analysis on Alpha Lenz.

What is Prime Medicine Inc. insider trading activity?

View the latest insider trading data for Prime Medicine Inc. on Alpha Lenz.

What is Prime Medicine Inc.'s P/E ratio?

Prime Medicine Inc.'s P/E ratio is -2.1.

Prime Medicine Inc.

NASDAQ · PRME
$2.87-0.03(-1.03%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Prime Medicine Inc.'s future dividend policy...
Alpha Chat Insight

Prime Medicine Inc. trades at a P/E of -2.1 (undervalued) with modest ROE of -146.8%.

Ask for details

Company Overview

Prime Medicine Inc. is a pioneering biotechnology company focused on the development of prime editing, a novel gene editing technology. This advanced approach aims to precisely edit the human genome by correcting genetic mutations at the DNA level without introducing double-strand breaks. Unlike traditional CRISPR methods, prime editing offers a higher level of accuracy and fewer unintended consequences, representing a transformative step in the treatment of genetic disorders. Prime Medicine operates within the cutting-edge sectors of biotechnology and healthcare, targeting therapeutic solutions for various genetic diseases that have remained challenging to treat with existing technologies. By leveraging prime editing, Prime Medicine seeks to address a wide spectrum of conditions, potentially revolutionizing personalized medicine and genomic interventions. The company's expertise in genetic editing plays a crucial role in advancing medical science and holds significant promise for improving patient outcomes and extending the frontiers of gene therapy.

CEODr. Allan Reine M.D.
SectorHealthcare
IndustryBiotechnology
Employees214

Company Statistics

FY 2025

Profile

$426.94MMarket Cap
$4.63MRevenue
0.00Shares Out
214Employees

Margins

N/AGross
-4349.33%EBITDA
-4498.06%Operating
-4342.44%Pre-Tax
-4342.44%Net

Valuation

-2.12P/E
3.53P/B
92.17EV/Sales
-2.38EV/EBITDA
-2.56P/FCF

Growth (CAGR)

N/ARev 3Yr
-2.32%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-62.83%ROA
-146.81%ROE
-65.08%ROIC

Financial Health

$63.03MCash & Cash Equivalents
$158.83MNet Debt
183.56%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Prime Medicine Inc. (ticker: PRME) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 214 employees. Market cap is $427M.

The current price is $2.87 with a P/E ratio of -2.12x and P/B of 3.53x.

ROE is -146.81% and operating margin is -4498.06%. Annual revenue is $5M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Prime Medicine Inc. (PRME) Stock Forecast 2026 $2.87 — Price, Financials & Analyst Targets | Alpha Lenz